Search
Ozanimod
go.drugbank.com/drugs/DB12612ApprovedInvestigationalOzanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approve...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesDihydralazine
go.drugbank.com/drugs/DB12945ApprovedWithdrawnDihydralazine is under investigation in clinical trial NCT00311974 (The Effect of Dihydralazine on Kidney Function and Hormones in Healthy Individuals).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsPexidartinib
go.drugbank.com/drugs/DB12978ApprovedInvestigationalPexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in Au...
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesBencyclane
go.drugbank.com/drugs/DB13488ExperimentalA vasodilator agent found to be effective in a variety of peripheral circulation disorders. It has various other potentially useful pharmacological effects. Its mechanism may involve block of calcium channels.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesPipemidic acid
go.drugbank.com/drugs/DB13823InvestigationalPipemidic acid is a quinolone antibacterial agent with activity against various gram-positive and gram-negative bacteria.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsPiperaquine
go.drugbank.com/drugs/DB13941ApprovedInvestigationalPiperaquine is an antimalarial agent first synthesized in the 1960's and used throughout China . Its use declined in the 1980's as piperaquine resistant strains of Plasmodium falciparum appeared and artemisinin derivatives became availab...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InhibitorsTenofovir
go.drugbank.com/drugs/DB14126InvestigationalTenofovir is an acyclic nucleotide diester analog of adenosine monophosphate. In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog....
Categories: P-glycoprotein substratesAdagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigationalAdagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations. However, the development of KRAS in...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesZavegepant
go.drugbank.com/drugs/DB15688ApprovedInvestigationalZavegepant (BHV-3500) is a calcitonin gene-related peptide (CGRP) receptor antagonist. CGRP is released from sensory nerves and acts as a strong vasodilator, and thanks to these properties, it is involved in pain pathways. CGRP receptors...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesLeniolisib
go.drugbank.com/drugs/DB16217ApprovedInvestigationalLeniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS). APDS is a ...
Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates